Prudential Financial Inc Lexicon Pharmaceuticals, Inc. Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$2.15 - $3.49 $106,640 - $173,104	-49,600 Reduced 49.03%	51,558 $118,000
Q1 2023 May 12, 2023	BUY	$1.99 - $2.68 $31,442 - $42,344	15,800 Added 18.51%	101,158 $245,000
Q3 2022 Nov 04, 2022	SELL	$1.94 - $3.43 $75,951 - $134,284	-39,150 Reduced 31.44%	85,358 $205,000
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $58,295 - $119,705	-44,500 Reduced 26.33%	124,508 $232,000
Q1 2022 May 13, 2022	SELL	$1.95 - $3.89 $157,365 - $313,923	-80,700 Reduced 32.32%	169,008 $353,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $951,387 - $1.54 Million	249,708 New	249,708 $984,000
Q1 2021 May 12, 2021	SELL	$3.45 - $9.09 $52,505 - $138,340	-15,219 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.05 - $3.67 $677 - $2,367	645 Added 4.43%	15,219 $52,000
Q3 2020 Nov 16, 2020	BUY	$1.44 - $2.1 $4,039 - $5,890	2,805 Added 23.83%	14,574 $21,000
Q2 2020 Aug 12, 2020	BUY	$1.75 - $2.3 $3,048 - $4,006	1,742 Added 17.37%	11,769 $23,000
Q1 2020 May 12, 2020	BUY	$1.8 - $4.28 $18,048 - $42,915	10,027 New	10,027 $19,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.